Cell Reports
Volume 19, Issue 9, 30 May 2017, Pages 1874-1887
ArticleA TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy
Under a Creative Commons license
open access
Graphical Abstract
Keywords
cancer immunotherapy
double-stranded RNA
innate immunity
PD-L1 blockade
priming adjuvant
Toll-like receptor 3
tumor-associated antigen
tumor immunity
vaccine immunotherapy
Cited by (0)
© 2017 The Authors.